BioLineRx Company Profile (NASDAQ:BLRX)

About BioLineRx (NASDAQ:BLRX)

BioLineRx logoBioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BLRX
  • CUSIP: N/A
  • Web:
  • Market Cap: $59.61 million
  • Outstanding Shares: 61,782,000
Average Prices:
  • 50 Day Moving Avg: $0.86
  • 200 Day Moving Avg: $0.96
  • 52 Week Range: $0.75 - $1.42
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 19.30
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.58 per share
  • Price / Book: 1.67
  • EBIDTA: ($17,590,000.00)
  • Return on Equity: -47.45%
  • Return on Assets: -42.90%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 6.12%
  • Quick Ratio: 6.12%
  • Average Volume: 366,583 shs.
  • Beta: 0.7
  • Short Ratio: 1.3
Frequently Asked Questions for BioLineRx (NASDAQ:BLRX)

What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) posted its quarterly earnings data on Thursday, May, 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.03. View BioLineRx's Earnings History.

Where is BioLineRx's stock going? Where will BioLineRx's stock price be in 2017?

4 brokerages have issued 12 month target prices for BioLineRx's stock. Their predictions range from $1.10 to $7.00. On average, they anticipate BioLineRx's share price to reach $3.62 in the next twelve months. View Analyst Ratings for BioLineRx.

What are analysts saying about BioLineRx stock?

Here are some recent quotes from research analysts about BioLineRx stock:

  • 1. According to Zacks Investment Research, "Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. " (6/20/2017)
  • 2. Maxim Group analysts commented, "BiolineRx announced the company has filed regulatory submissions for three BL-8040 + Tecentriq (PD-L1) P1b studies; pancreatic cancer, gastric cancer and lung cancer. The studies are expected to initiate in 2H17." (6/1/2017)

Who are some of BioLineRx's key competitors?

Who are BioLineRx's key executives?

BioLineRx's management team includes the folowing people:

  • Aharon Schwartz, Chairman of the Board
  • Philip Adam Serlin, Chief Executive Officer
  • Mali Zeevi, Chief Financial Officer
  • Merril Gersten, Chief Scientific Officer
  • Moshe Phillip M.D., Vice President of Medical Affairs and Senior Clinical Advisor
  • David Malek, Vice President - Business Development
  • Leah Klapper, General Manager, BioLine Innovations Jerusalem
  • Michael J. Anghel, Director
  • Jacob Friedman, Director
  • Raphael Hofstein, Director

How do I buy BioLineRx stock?

Shares of BioLineRx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioLineRx's stock price today?

One share of BioLineRx stock can currently be purchased for approximately $0.96.

MarketBeat Community Rating for BioLineRx (NASDAQ BLRX)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  288
MarketBeat's community ratings are surveys of what our community members think about BioLineRx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioLineRx (NASDAQ:BLRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.62 (275.17% upside)

Analysts' Ratings History for BioLineRx (NASDAQ:BLRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Maxim GroupSet Price TargetBuy$3.00HighView Rating Details
6/3/2017HC WainwrightSet Price TargetBuy$4.00MediumView Rating Details
2/13/2017Rodman & RenshawInitiated CoverageBuy$3.00N/AView Rating Details
11/28/2016Roth CapitalReiterated RatingBuy$7.00N/AView Rating Details
9/23/2016S&P Equity ResearchLower Price Target$1.24 -> $1.10N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$3.50 -> $3.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$3.50 -> $3.00N/AView Rating Details
(Data available from 7/23/2015 forward)


Earnings History for BioLineRx (NASDAQ:BLRX)
Earnings by Quarter for BioLineRx (NASDAQ:BLRX)
Earnings History by Quarter for BioLineRx (NASDAQ BLRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/25/20173/31/2017($0.05)($0.08)$0.01 millionViewN/AView Earnings Details
3/23/201712/31/2016($0.08)($0.13)$0.02 millionViewN/AView Earnings Details
11/22/2016Q316($0.07)($0.08)ViewN/AView Earnings Details
8/11/2016Q216($0.07)($0.07)ViewListenView Earnings Details
5/17/2016Q116($0.08)($0.10)ViewListenView Earnings Details
3/10/2016Q415($0.06)($0.07)ViewListenView Earnings Details
11/16/2015Q315($0.08)($0.03)ViewListenView Earnings Details
8/20/2015Q215($0.10)($0.09)ViewListenView Earnings Details
5/18/2015Q115($0.10)($0.08)ViewListenView Earnings Details
11/10/2014Q314($0.11)($0.02)ViewN/AView Earnings Details
8/6/2014Q214($0.09)($0.12)ViewN/AView Earnings Details
5/20/2014Q114($0.11)($0.01)ViewN/AView Earnings Details
3/17/2014($0.15)($0.20)ViewN/AView Earnings Details
11/13/2013($0.18)($0.20)ViewN/AView Earnings Details
8/6/2013Q213($0.02)ViewN/AView Earnings Details
5/7/2013($0.02)($0.20)ViewN/AView Earnings Details
11/14/2012Q312($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioLineRx (NASDAQ:BLRX)
Current Year EPS Consensus Estimate: $-0.2400 EPS
Next Year EPS Consensus Estimate: $0.0500 EPS


Dividend History for BioLineRx (NASDAQ:BLRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for BioLineRx (NASDAQ:BLRX)
No insider trades for this company have been tracked by


Headline Trends for BioLineRx (NASDAQ:BLRX)
Latest Headlines for BioLineRx (NASDAQ:BLRX)
DateHeadline logoInvestors Waiting In BioLineRx - Seeking Alpha - July 18 at 6:06 PM logoBioLineRx Ltd. (NASDAQ:BLRX) Receives Consensus Rating of "Buy" from Brokerages - July 17 at 11:14 PM logoBioLineRx: At Around $1, This Sleeper Biotech Stock Is A Strong Buy - Seeking Alpha - July 13 at 5:35 PM logoBioLineRx (BLRX) Begins Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration - - July 11 at 4:54 PM logoBioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration - July 10 at 4:34 PM logoTop 10 Penny Stocks To Buy in 2017 - June 29 at 5:44 PM logoCorporate News Blog - Concordia Announces Review of Strategic Alternatives; Views Itself on the Auction Block to Repay its $3.5 billion Debt - June 23 at 4:34 PM logoBioLineRx Ltd. (BLRX) Downgraded by Zacks Investment Research to "Sell" - June 20 at 7:56 PM logoBioline RX Ltd (BLRX) PT Set at $4.00 by HC Wainwright - June 4 at 11:46 PM logoBioLineRx (BLRX) Announces Submission of Three Phase 1b Trials ... - - June 1 at 4:25 PM logoBioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors - June 1 at 4:25 PM logoMaxim Group Reiterates Buy Rating for Bioline RX Ltd (BLRX) - June 1 at 4:14 PM logoBioline RX Ltd (BLRX) Lifted to "Buy" at Zacks Investment Research - May 29 at 8:26 PM logoBioline RX Ltd (BLRX) Given a $4.00 Price Target at HC Wainwright - May 27 at 9:34 AM logoBioline RX Ltd (BLRX) Downgraded to Hold at Zacks Investment Research - May 26 at 7:14 PM logoBioline RX Ltd (BLRX) Posts Earnings Results, Misses Expectations By $0.03 EPS - May 26 at 8:24 AM logoMaxim Group Analysts Give Bioline RX Ltd (BLRX) a $3.00 Price Target - May 25 at 8:36 PM logoBioLineRx Reports First Quarter 2017 Financial Results - PR Newswire (press release) - May 25 at 5:01 PM logoBioLineRx Reports First Quarter 2017 Financial Results - May 25 at 5:01 PM logoInvestor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - May 25 at 5:01 PM logoBioLineRx (BLRX) Files BL-8040 Phase 1b Trial Regulatory Submission in Combo with atezolizumab in AML - - May 24 at 8:53 PM logoBioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML - May 22 at 11:40 AM logo[$$] BiolineRX Shares Could Triple - May 19 at 3:53 PM logoBioline RX Ltd (BLRX) Lifted to "Buy" at Maxim Group - May 18 at 8:34 AM logoBioLineRx to Report First Quarter 2017 Results on May 25, 2017 - May 16 at 12:35 PM logoBioLineRx (BLRX) Initiate Phase 3 Study with BL-8040 Following Successful Meeting with FDA - - May 3 at 10:48 AM logoBioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA - May 3 at 10:48 AM logoSomewhat Favorable Press Coverage Extremely Likely to Affect Bioline RX (BLRX) Share Price - April 28 at 9:48 AM logoShort Interest in Bioline RX Ltd (BLRX) Expands By 58.7% - April 26 at 11:50 PM logoBioline RX (BLRX) Given News Impact Score of 0.19 - April 25 at 12:37 PM logoBioline RX Ltd (BLRX) Rating Increased to Buy at Zacks Investment Research - April 21 at 8:28 PM logoBiolineRx: COMBAT Engagement - Seeking Alpha - April 20 at 4:03 PM logoBioline RX (BLRX) Getting Very Favorable Press Coverage, Report Finds - April 14 at 11:12 AM logoBioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares - April 7 at 8:33 AM logoToday's Research Reports on Biotech Stocks to Watch: Bioline RX and Cara Therapeutics - April 3 at 4:21 PM logoBioLineRx (BLRX) to Offer ADSs - - March 31 at 9:04 PM logoBioLineRx (BLRX) Prices 29.4M Offering at $0.85/ADS - - March 31 at 9:04 PM logoMid-Day Market Update: Sorl Auto Parts Rises After Q4 Results; Bioline RX Shares Drop - March 31 at 4:04 PM logoBioLineRx Prices $25 Million Underwritten Public Offering - March 31 at 4:04 PM logoBioLineRx Announces Underwritten Public Offering of its American Depositary Shares - March 30 at 4:22 PM logoBIOLINERX LTD. Financials - March 28 at 6:07 PM logoBioLineRx's AGI-134 to be Presented at AACR 2017 - March 27 at 11:40 AM logoBioLineRx's (BLRX) CEO Philip Serlin on Q4 2016 Results ... - Seeking Alpha - March 25 at 3:55 PM logoBioLineRx (BLRX) Acquires Agalimmune - - - March 24 at 3:19 PM logoBioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline - March 23 at 4:21 PM logoBioLineRx Reports Year End 2016 Financial Results - March 23 at 4:21 PM logoBioline RX Ltd (BLRX) PT Set at $1.00 by Maxim Group - March 21 at 3:39 PM logoBioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment - March 20 at 11:29 AM logo7:01 am BioLineRx reports partial results data from its open-label Phase 2 trial for BL-8040 as a novel monotherapy approach for the mobilization and collection of blood forming stem and progenitor cells from the peripheral blood; top-line - March 20 at 11:29 AM logoBioLineRx to Report Annual 2016 Results on March 23, 2017 - March 16 at 3:17 PM



BioLineRx (BLRX) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by Staff